ATTENTION BCYC Investors: Securities Fraud Investigation Underway - Contact Levi & Korsinsky

New York, New York--(Newsfile Corp. - November 18, 2025) - Levi & Korsinsky notifies investors that it has commenced an investigation of Bicycle Therapeutics plc ("Bicycle Therapeutics plc") (NASDAQ: BCYC) concerning possible violations of federal securities laws.

On October 31, 2025, RBC Capital Markets analyst Leonid Timashev downgraded Bicycle to Sector Perform from Outperform, citing delays in development of zelenectide pevedotin, which is in phase 2/3 development for metastatic urothelial cancer, due to pushing dose selection to the first quarter of 2026. Timashev noted that the urothelial cancer treatment space is growing more competitive, and asserted that any further delays from Bicycle will only help sales of a competing Pfizer product.

Following this news, Bicycle's American Depositary Receipt ("ADR") price fell over 7% on the same day. To obtain additional information, go to:

https://zlk.com/pslra-1/bicycle-therapeutics-plc-lawsuit-submission-form?prid=177998&wire=5&utm_campaign=58

or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212)363-7500.

WHY LEVI & KORSINSKY: Over the past 20 years, Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. Attorney Advertising. Prior results do not guarantee similar outcomes.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/275058